Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.51 |
| ▸ | CNR2 | P34972 | 11/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045979 | 0.90 | GAA (0.55) | CNR1CNR2GAAHTT | |
| SCHEMBL1043280 | 0.87 | CNR2 (0.42) | CNR2TP53HPGDSMN1; SMN2TDP1 | |
| SCHEMBL13356144 | 0.87 | CNR2 (0.46) | CNR1CNR2TP53HPGDTDP1 | |
| SCHEMBL3241183 | 0.86 | GAA (0.43) | CNR1CNR2GAAHTTTP53 | |
| SCHEMBL25725902 | 0.80 | CNR2 (0.43) | CNR1CNR2HTTTP53HPGD | |
| SCHEMBL1042951 | 0.78 | CNR1 (0.45) | CNR1CNR2GAAHTTHPGD | |
| SCHEMBL1043213 | 0.77 | CNR2 (0.46) | CNR1CNR2GAAHTTTP53 | |
| SCHEMBL1042854 | 0.76 | LMNA (0.46) | CNR2TP53HPGDTDP1 | |
| SCHEMBL1041186 | 0.76 | GAA (0.45) | CNR2GAAHTTHPGDTSHR | |
| SCHEMBL1044635 | 0.76 | GAA (0.45) | CNR2GAAHTTTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | CNR1 4520/4885CNR2 4708/4885GAA 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.